Diaceutics (GB:DXRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Diaceutics PLC has announced a groundbreaking partnership with a major biotech company to promote a new oncology precision medicine in the US, leveraging its PMx services. The deal, worth up to £4.3 million over 18 months, aligns Diaceutics’ revenue with patient recruitment, marking a new era for the company’s growth and commitment to ensuring patients receive optimal treatments. This partnership highlights Diaceutics’ innovative approach to precision medicine commercialization and its potential for extended collaboration beyond 2025.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.